These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 30248527)

  • 21. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
    Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
    J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage-dependent immunity orchestrates AQP4 antibody-guided NMOSD pathology: a role for netting neutrophils with resident memory T cells in situ.
    Nakajima A; Yanagimura F; Saji E; Shimizu H; Toyoshima Y; Yanagawa K; Arakawa M; Hokari M; Yokoseki A; Wakasugi T; Okamoto K; Takebayashi H; Fujii C; Itoh K; Takei YI; Ohara S; Yamada M; Takahashi H; Nishizawa M; Igarashi H; Kakita A; Onodera O; Kawachi I
    Acta Neuropathol; 2024 Apr; 147(1):76. PubMed ID: 38658413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks and outcomes of pregnancy in neuromyelitis optica spectrum disorder: A comprehensive review.
    Siriratnam P; Huda S; Butzkueven H; van der Walt A; Jokubaitis V; Monif M
    Autoimmun Rev; 2024 Feb; 23(2):103499. PubMed ID: 38061621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal dysfunction in AQP4 NMOSD and MS; a potential predictor of relapse and prognosis.
    Chen Y; Wang Y; Jin R; Lv Z; Fu Y; Teng J; Wang X
    Clin Immunol; 2024 Feb; 259():109875. PubMed ID: 38141747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.
    Sen S; Tuncer A; Terzi M; Bunul SD; Ozen-Acar P; Altunrende B; Ozakbas S; Tutuncu M; Uygunoglu U; Akman-Demir G; Karabudak R; Efendi H; Siva A
    Mult Scler Relat Disord; 2023 Nov; 79():104949. PubMed ID: 37678131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil.
    Silva GD; Apóstolos-Pereira SL; Callegaro D
    Mult Scler Relat Disord; 2023 Feb; 70():104488. PubMed ID: 36610359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder.
    Schmetzer O; Lakin E; Roediger B; Duchow A; Asseyer S; Paul F; Siebert N
    Front Neurol; 2021; 12():635419. PubMed ID: 33776892
    [No Abstract]   [Full Text] [Related]  

  • 28. Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.
    Liu J; Xu L; Chen ZL; Li M; Yi H; Peng FH
    Bosn J Basic Med Sci; 2018 Feb; 18(1):35-42. PubMed ID: 29144890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.
    Bennett JL; Fujihara K; Kim HJ; Marignier R; O'Connor KC; Sergott RC; Traboulsee A; Wiendl H; Wuerfel J; Zamvil SS; Anania VG; Buffels R; Künzel T; Lekkerkerker AN; Lennon-Chrimes S; Pittock SJ
    Front Neurol; 2023; 14():1114667. PubMed ID: 36873431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causal associations between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian randomization study.
    Wang L; Zhou L; ZhangBao J; Huang W; Tan H; Fan Y; Lu C; Yu J; Wang M; Lu J; Zhao C; Zhang T; Quan C
    Eur J Neurol; 2023 Dec; 30(12):3819-3827. PubMed ID: 37540821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-Based Assay to Detect the Autoantibody Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD).
    Chatterjee P; Saha S; Mukhopadhyay D
    Methods Mol Biol; 2024; 2761():121-133. PubMed ID: 38427234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
    Arnett S; Chew SH; Leitner U; Hor JY; Paul F; Yeaman MR; Levy M; Weinshenker BG; Banwell BL; Fujihara K; Abboud H; Dujmovic Basuroski I; Arrambide G; Neubrand VE; Quan C; Melamed E; Palace J; Sun J; Asgari N; Broadley SA;
    J Neurol; 2024 Aug; 271(8):4794-4812. PubMed ID: 38958756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility-weighted image features in AQP4-negative-NMOSD versus MS.
    Gao C; Su L; Li H; Song T; Liu Y; Duan Y; Shi FD
    Mult Scler Relat Disord; 2024 Feb; 82():105406. PubMed ID: 38176283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: An integrative review of demographic and laboratory factors.
    Guo RY; Wang WY; Huang JY; Jia Z; Sun YF; Li B
    Mult Scler; 2024 Jan; 30(1):7-15. PubMed ID: 37982449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Papp V; Magyari M; Möller S; Sellebjerg F; Battistini JL; Svendsen KB; Søndergaard HB; Nilsson AC; Illes Z
    Neurology; 2024 Mar; 102(5):e209147. PubMed ID: 38546185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromyelitis optica spectrum disorder: Do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective.
    Ortiz Salas PA; Gaviria Carrillo M; Cortés Bernal GA; Moreno Medina K; Roa LF; Rodríguez Quintana JH
    Neurologia (Engl Ed); 2020 Nov; ():. PubMed ID: 33162220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between neuromyelitis optica spectrum disorder and autoimmune diseases.
    Lin J; Xue B; Li J; Xie D; Weng Y; Zhang X; Li X; Xia J
    Front Immunol; 2024; 15():1406409. PubMed ID: 38994358
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Pandit L; Cox LM; Malli C; D'Cunha A; Rooney T; Lokhande H; Willocq V; Saxena S; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33148687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case report: Overlap syndrome of neuromyelitis optica spectrum disorder with anti-Argonaute antibodies.
    Liu P; Lin X; Wu S
    Front Immunol; 2024; 15():1366531. PubMed ID: 38887290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric Neuromyelitis Optica Spectrum Disorder.
    Poisson K; Moeller K; Fisher KS
    Semin Pediatr Neurol; 2023 Jul; 46():101051. PubMed ID: 37451749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.